The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prevalence of autosomal dominant polycystic kidney disease in the European Union
Open accessAbstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease, but estimates of its prevalence vary by >10-fold. The objective of this study was to examine the public health impact of ADPKD in the European Union (EU) by estimating minimum prevalence (point prevalence of known cases) and screening prevalence (minimum prevalence plus cases expected after population-based screening). Methods: A review of the epidemiology literature from January 1980 to February 2015 identified population-based studies that met criteria for methodological quality. These examined large German and British populations, providing direct estimates of minimum prevalence and screening prevalence. In a second approach, patients from the 2012 European Renal Association‒European Dialysis and Transplant Association (ERA–EDTA) Registry and literature-based inflation factors that adjust for disease severity and screening yield were used to estimate prevalence across 19 EU countries (N = 407 million). Results: Population-based studies yielded minimum prevalences of 2.41 and 3.89/10 000, respectively, and corresponding estimates of screening prevalences of 3.3 and 4.6/10 000. A close correspondence existed between estimates in countries where both direct and registry-derived methods were compared, which supports the validity of the registry-based approach. Using the registry-derived method, the minimum prevalence was 3.29/10 000 (95% confidence interval 3.27–3.30), and if ADPKD screening was implemented in all countries, the expected prevalence was 3.96/10 000 (3.94–3.98). Conclusions: ERA–EDTA-based prevalence estimates and application of a uniform definition of prevalence to population-based studies consistently indicate that the ADPKD point prevalence is <5/10 000, the threshold for rare disease in the EU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Cited by
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Autosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing
Lanktree, M. B., Haghighi, A., Guiard, E., Iliuta, I.-A., Song, X., Harris, P. C., Paterson, A. D., & Pei, Y. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050493 · Cited by 300
Opportunities and Challenges for Molecular Understanding of Ciliopathies–The 100,000 Genomes Project
Wheway, G., Genomics England Research Consortium, & Mitchison, H. M. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00127 · Cited by 99
Metadata
- Authors
- Willey, C. J., Blais, J. D., Hall, A. K., Krasa, H. B., Makin, A. J., & Czerwiec, F. S.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-20
- Volume
- 32
- Issue
- 8
- Pages
- 1356-1363
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2433595988
- Cited by
- 249
- References
- 1
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of autosomal dominant polycystic kidney disease in the European Union. https://app.cochat.ai/papers/10.1093/ndt/gfw240
- The paper
- Willey, C. J., Blais, J. D., Hall, A. K., Krasa, H. B., Makin, A. J., & Czerwiec, F. S. (2017). Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfw240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.